MYC ASO Impedes Tumorigenesis and Elicits Oncogene Addiction in Autochthonous Transgenic Mouse Models of HCC and RCC
Open Access
- 1 September 2020
- journal article
- research article
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 21, 850-859
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (CA170378, CA208735, R01 CA184384, U01 CA188383)
- National Cancer Institute (CA222676)
This publication has 22 references indexed in Scilit:
- Extrachromosomal oncogene amplification in tumour pathogenesis and evolutionNature Reviews Cancer, 2019
- Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome AtlasCell Systems, 2018
- Drugging the 'undruggable' cancer targetsNature Reviews Cancer, 2017
- Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneityNature, 2017
- MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolismProceedings of the National Academy of Sciences, 2015
- MYC Activation Is a Hallmark of Cancer Initiation and MaintenanceCold Spring Harbor Perspectives in Medicine, 2014
- MYC on the Path to CancerCell, 2012
- MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancerNature, 2004
- Sustained Loss of a Neoplastic Phenotype by Brief Inactivation of MYCScience, 2002
- Reversible Tumorigenesis by MYC in Hematopoietic LineagesMolecular Cell, 1999